top of page

Jardiance data shows reduced risk of CV death in type 2 diabetes

New data for Jardiance (empagliflozin), presented at the American Diabetes Association 76th Scientific Sessions, show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page